Arcturus Therapeutics to Present Ornithine Transcarbamylase (OTC) Deficiency Phase 2 Clinical Data and Provide Update on mRNA Liver Therapeutics Platform

A Phase 1 trial of Arcturus Therapeutics' self-amplifying mRNA H5N1 flu vaccine, ARCT-2304, showed strong immune responses and durability when doses were spaced eight weeks apart. The vaccine, encoding both HA and NA antigens, was well-tolerated across dose levels. The study, funded by U.S. HHS, suggests potential for pandemic preparedness.

Citigroup upgraded Arcturus Therapeutics to Buy from Neutral and raised its price target to $20 from $8. The stock has seen a 5-day change of $13.30, a 1st Jan change of -7.51%, and a 1-year change of +116.97%. The upgrade is based on a weighted average of ratings including valuation, EPS revisions, and visibility.

Arcturus Therapeutics (ARCT) shares rose 5.3% after reporting positive Phase 2 data for ARCT-810 and introducing LUNAR 2.0, a next-gen mRNA platform. The company plans to integrate ARCT-2601 into its Phase 2 study by 2026 and will acquire myNEO to enhance AI-driven mRNA design.

Arcturus Therapeutics (ARCT) shares rose 10.7% after announcing participation in five investor conferences in September 2026, signaling confidence in its pipeline. The company has a cash position of $191M and a strategic collaboration with Thermo Fisher. Analysts maintain a Buy rating, and the stock hit a session high of $16.45, despite broader market declines.

Arcturus Therapeutics (ARCT) shares surged over 60% this week, driven by sector-wide enthusiasm for mRNA technology and company-specific progress. The rally began after positive late-stage results from Merck and Moderna's mRNA cancer vaccine. ARCT's pipeline focuses on rare diseases, with key trials expected to report data in 2026. The company recently regained full rights to its COVID vaccine, KOSTAIVE, and has a solid balance sheet. Despite recent challenges, retail sentiment has turned extrem

Eloxx Pharmaceuticals (ELOX) rose 20% after FDA cleared its Phase 2b trial for exaluren. Vogenx (VOGX) gained 14% post-IPO. Arcturus (ARCT) advanced 21% on pipeline updates. Zhengye (ZYBT) +7% after Nasdaq compliance. Greenwich (GLSI) +10% on extended lock-up. HeartSciences (HSCS) +8% after $1M investment. AC Immune (ACIU) +8% on Phase 1 data.